ActHIB set to finally reach the Japanese market
This article was originally published in Scrip
The much-delayed Japanese launch of Sanofi Pasteur-Daiichi Sankyo Vaccines' paediatric meningitis vaccine ActHIB will take place on December 19th. The Haemophilus influenzae type b prophylactic vaccine was approved in the country back in January 2007, but batch production to Japanese standards took longer than expected. The product will be distributed by Daiichi Sankyo, and is not currently eligible for reimbursement under Japan's national insurance scheme.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.